Natco Pharma rises on getting USFDA`s tentative approval for Trabectedin for Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Natco Pharma is currently trading at Rs. 659.70, up by 8.40 points or 1.29% from its previous closing of Rs. 651.30 on the BSE.
The scrip opened at Rs. 663.95 and has touched a high and low of Rs. 669.00 and Rs. 657.50 respectively. So far 9139 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 993.45 on 06-Sep-2021 and a 52 week low of Rs. 607.95 on 31-May-2022.
Last one week high and low of the scrip stood at Rs. 684.85 and Rs. 636.70 respectively. The current market cap of the company is Rs. 11889.95 crore.
The promoters holding in the company stood at 48.80%, while Institutions and Non-Institutions held 26.95% and 24.25% respectively.
Natco Pharma has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection (generic for Yondelis ) for the 1mg/vial presentation. According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
